Author Details

Scroll

Refine your search

Collections

Medical Collection

Co-Authors

Journals

Research Journal of Pharmacy and Technology

Year

2019

Authors

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

Bharath Raj, K. C.

Ameliorative Potential of Eclipta albaon Gentamycin Induced Renal Toxicity in Rats

Abstract Views :171 | PDF Views:0

Authors

Prince Thomas ¹, M. P. Gururaja ¹, Himanshu Joshi ¹, K. Prasannashama ¹, Ullas D’Souza ¹, Nimmy Chacko ¹, K. C. Bharath Raj ¹, K. S. Rajesh ¹

Affiliations
1 NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Mangalore, IN

Source

Research Journal of Pharmacy and Technology, Vol 12, No 1 (2019), Pagination: 192-196

Abstract

Nephrotoxicity is a common event, which can cause significant morbidity and can be easily overlooked. Gentamycin is an antimicrobial agent which can cause nephrotoxicity on prolonged use. A large number of herbs have traditionally been used to treat drug or toxin-induced renal diseases. The present study was a similar attempt in that direction to evaluate the nephroprotective activity of ethanolic extract of whole plant of Eclipta alba against gentamycin induced nephrotoxicity. The animals were divided into five groups (n=6) consisting of normal control, toxic control and three test groups which received different doses of the extract (100,200 & 400mg/kg, p.o). Nephroprotective effect of ethanolic extract of Eclipta alba was evaluated by assessing the blood parameters and histopathological studies of kidney. Elevated levels of serum urea, serum creatinine, total protein and uric acid have been significantly reduced in dose depending manner by oral administration of ethanolic extract of whole plant of Eclipta alba. These observations were supported by histopathological studies.

Keywords

Eclipta alba, Gentamycin, Nephrotoxicity, Nephroprotection.

Full Text

References

Iqbal H, Naeem K, Riaz U, Shanzeb, Shabir A, Farhat AK., et al. Phytochemical, physiochemical and anti-fungal activity of Eclipta alba. Afr. J. Pharm. Pharmacol 2011;5(19):2150-5.

NazimUddin, AtiarRahman, SohelRana, RashedaAkter, Masudul Azad Chowdhury. Antioxidant, cytotoxic and antimicrobial properties of Eclipta alba ethanol extract. Int J Biol Med Res 2010;1(4):341–6.

New OCED 425 guidelines. OCED Guidelines for testing animals.2001 Dec 1; 26: 1-26.

Turner RA. Screening methods in pharmacology. New York: Academic press INC; 1965.

Kaplan A, Lavernal LS. Clinical Chemistry: Interpretation and techniques. 2^nd ed. Philadelphia: Lea and Febiger; 1983.

Murray RL. Non protein Nitrogen Compounds. In: Kaplan LA, Pesce AJ, Eds. Clinical Chemistry: Theory, Analysis and Corelation. Toranto:Mosby; 1984.p. 1230-68.

Koller A .Proteins. In: Kaplan LA, PesceAJ, editors. Clinical Chemistry:Theory, Analysis and Co-relation. Toranto:Mosby; 1984.p.1268-1327.

Wootton IDP. Micro-analysis in Medical Biochemistry.4^th ed. London: Churchil Livingstone;1964. p.86.

Sudhavani V, Chinnikrishnaiah V, Raghu MV, Raghavendra HG, Ranganayakulu D. Nephroprotective activity of Merremiaemarginataburm against cisplatin induced nephrotoxic rats. Journal of Advances in Drug Research 2010; 1( 1):27-34.

LakshmiB V S, Sudhakar M. Protective effect of Zingiber officinale on gentamycin induced nephrotoxicity in rats. Int. J. Pharmacol 2010;1:1-5.

Devipriya S, Shyamaladevim CS. Protective effect of quercetin in cisplatininduced cell injury in the rat kidney. Indian J. Pharmacol 1999; 31: 422.

Drug Prescription Pattern in Paediatric Respiratory Tract Infections

Abstract Views :146 | PDF Views:0

Authors

Anaghya V. Naik ¹, Hebsiba Joseph ¹, Nidhina Mathew ¹, Sumanth Shetty ², K. S. Rajesh ¹, K. C. Bharath Raj ¹, Juno J. Joel ¹, M. P. Gururaj ³, U. P. Nandakumar ¹

Affiliations
1 Department of Pharmacy Practice, NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Mangaluru, IN
2 Department of Paediatric, K S Hegde charitable Hospital, Nitte (Deemed to be University), Mangaluru, IN
3 Department of Pharmacology, NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Mangaluru, IN

Source

Research Journal of Pharmacy and Technology, Vol 12, No 3 (2019), Pagination: 1280-1284

Abstract

Objective: To develop baseline data on drug prescribing pattern and evaluate the rationality of prevalent prescribing practices using WHO core indicators. Methodology: A prospective observational study was carried out for a period of 6 months in the paediatric population having respiratory tract infections. Results: A total of 211 prescriptions were analysed in the study, in which, 124(58.8%) patients were male and 87(41.2%) were female. Paediatric population of the age group 1-3 years were more prone to respiratory tract infections and common disease diagnosed was unspecified lower respiratory tract infection. A total of 885 drugs were prescribed and most commonly prescribed drug was found to be paracetamol-143(67.8%), followed by salbutamol-128 (60.66%), amoxicillin+ clauvalanic acid-93 (44.1%) and budesonide-77 (36.5%). 261(29.49%) oral, 224(25.31%) inhalations, 231(26.1%) injectables were prescribed. 158 fixed dose combination were prescribed. Drugs per prescription was found to be 4.1. 14.01% drugs were prescribed with generic names and 77.4% were prescribed from WHO model list of essential drugs. Percentage of antibiotic prescribed was 93% and injection was 84.36%. The consultation time taken by physician raged between 8-12 minutes and time taken by pharmacist to dispense drugs was 6-14 minutes. Conclusion: The present study was conducted to analyse the rational prescribing of drugs in the paediatric department of a tertiary care hospital using WHO core indicators. Males were more prone to respiratory tract infections and amoxicillin+ clavulanic acid was the most prescribed antibiotic and paracetamol was the most commonly prescribed drug. The study highlights few limitations focusing on the facility indicators due to lack of EDL, hospital formulary or standard guidelines and therefore consideration for better patient care and increased quality of life needs to be monitored. Review on prescribing and dispensing of drugs needs to be done regularly.

Keywords

WHO Core Indicators, Prescription Pattern, Respiratory Tract Infection, Antibiotic, Generic Drugs.

Full Text

References

Gedam D S, Patel U, Verma M, Gedam S, Chourishi A. Drug prescription pattern in paediatric outpatient department. Int J Pharm Sci Rev Res. 2012; 17(2): 42-45.

Goel K, Khanna S, Verma A, Shankar P, Chopra V S, Dixit R K. Drug prescribing pattern in the outpatient department of paediatrics. IJPSR.2013; 4(4): 78-80.

Parthasarathy A, Menon P S, Agarwal RK, Editors. IAP Textbook of Paediatrics: 4ed. New Delhi: Jaypee; 2009.212-218.

Arnold HM, Deal EN, Gelone S, Micek SP et.al. Applied Therapeutics the Clinical Use of Drugs, 10ed. United States of America: Lippincott Williams & Wilkins; 2013; 1514-1515.

Al-Balushi K A, Sawafi F, Ghafri F, ZakwaniL. Drug utilization pattern in an Omani paediatric population. JBCP. 2013; 4(3):68-72.

Iyer G S, Patel P P, Panchal J R, Dikshit R K. An analysis of pharmacological management of respiratory tract infection in paediatric. IJMPH. 2013; 3(3): 140-145.

Parthasarathy A, Kundu R, Choudhury J, Editors. Textbook of Paediatric Infectious Diseases: New Delhi: Jaypee; 2013.114-116.

Ghosh A, Das A K, Gure P K, Pati S. An observational study of drugs in URTI in a tertiary care hospital in Kolkata. Asian J Pharm Clin Res. 2015; 8(4):37-40.

Nandimath M K, Ahuja A S. Drug prescribing pattern in upper respiratory tract infection in children aged 1-14 years. IJPBS.2012; 3(1):299-308.

Sharma S, Agrawal G. A study on drug prescribing pattern in URTI among children aged 1-12 years. IJBCP.2016; 5(2):406-410.

Beg M A, Dutta S B, Bawa S, Kaur A, Vishal S, Kumar U. Prescribing trends in respiratory tract infections in a tertiary care teaching hospital. Int J Res Med Sci. 2017; 5(6): 2588-2591.

Joseph F ,Oladela O, Oludare O, Olatune O .Drug prescribing pattern for under 5 in a paediatric clinic in south western ,Nigeria. Ethiop J Health Science. 2015; 25 (1):73-77.

Alkahtani S A. Drug utilisation pattern of upper respiratory tract infection in paediatric at Najran University Hospital. Biomedical Research.2017; 28(20):8981-8986.

Vishwanath M, Reddy N, Devdas S. Assessment of drug utilization in hospitalized children at tertiary care Teaching Hospital. JOCPR.2014; 6(2):592-598.

Mohsin N, Shahzad N, Akhtar M S, Zahak A, Almalki A, Alzailay M H et al. Drug utilization pattern for upper respiratory tract infections in paediatrics at a university teaching hospital. BEPLS.2016; 6(1):22-27.

Jhansi M, Vijaya K S, Manigandan L S, Priyarajam V. Patterns of prescription and drug use in paediatric department of lower respiratory tract infection. RJPBCS. 2015; 6(2): 1207-1215.

Gairola B, Devarsi C, Daisy P, Anupama D. Drug prescription pattern in RTI in children aged 1-12 years. J Pharm Biomed Sci. 2016; 6(10): 537-545.

A Study on Treatment Defaulters in Tuberculosis Patients on Dots Therapy

Abstract Views :175 | PDF Views:0

Authors

Mohammed Shabil ¹, V. Rajesh ², K. C. Bharath Raj ¹, K. S. Rajesh ¹, K. Prasanna Shama ³, M. P. Gururaja ³, Himanshu Joshi ³

Affiliations
1 Department of Pharmacy Practice, NITTE (Deemed to be University), Mangaluru - 575018 Karnataka, IN
2 Department of Pulmonary Medicine, NITTE (Deemed to be University), Mangaluru - 575018 Karnataka,, IN
3 Department of Pharmacology, NITTE (Deemed to be University), Mangaluru - 575018 Karnataka, IN

Source

Research Journal of Pharmacy and Technology, Vol 12, No 5 (2019), Pagination: 2245-2253

Abstract

Tuberculosis is an infectious airborne, chronic granulomatous bacterial disease which requires a prolonged treatment to get a complete cure and prevent death, relapse, resistance to drugs and spreading it to the community. Present study was focused on treatment defaulters among tuberculosis patients receiving dots therapy. A prospective observational study was carried out in the in-patient and outpatient department of pulmonary medicine and other departments with dots referral in a hospital setting for a period of eight months from September 2017- April 2018. During the study period all the patients who was administered with dots therapy for the treatment of tuberculosis were enrolled as per the study criteria. All the patients were interviewed to know there treatment status and also monitored there ADR to check compliance with dots therapy. All the datas were analyzed using descriptive statistics. Out of 90 patients, 21 patients interrupted the treatment, of which 12 were defaulters. The overall percentage of the default to the treatment was 13.3%. The case fatality rate was 4.4%. The mean age of defaulting was found to be 53.3 years and the highest percentage were in the age group 50-65years. Male patients, rural domicile, patients pursuing primary education, pulmonary TB patients were high among the defaulters. Distance (58.3%) transportation (25%), staying alone (16.7%), workload (25%) were the general problems felt by the defaulters. 41.7% were dissatisfied with the behavior of dots provider and 50% of them did not have family support. Patients interrupted treatment in there early phases (41.7% in intensive phase and 58% in early continuous phase). The reasons to default were feeling of wellbeing after the treatment (41.7%), side effects (25.0%). Migration, non-availability of medicines, affording transport charges, medical issues were the other reasons (8.3%). Out of 90 patients, 17 (18.9%) patients came out with a total of 24 ADRs. From this only 2 patients had defaulted from the treatment due to intolerance from the medicational Side effects. ADR monitoring improved the knowledge (from 4.9 to 8.2) and treatment (1.2 to 2.5) of the patient in the current study. From the study we came to conclude that Defaulting was seen mainly due to unawareness, carelessness, disbelief of the treatment method. This can be enhanced by patient education, interviewing them periodically, Monitoring the treatment condition and side effects. So the Clinical pharmacists is responsible in promoting the dots therapy to improve the patients adherence towards it, there by achieving a well treatment outcome.

Keywords

Tuberculosis, DOTS Therapy, Default, ADR Monitoring.

Full Text

References

Tuberculosis (TB) [Internet]. World Health Organization; 2018 [updated 2018Jan; cited 2018 Apr9]. Available from: http://www.who.int/mediacentre/factsheets/fs104/en/

Gorityala SB, Mateti UV, Venkateswarlu Konuru SM. Assessment of treatment interruption among pulmonary tuberculosis patients: A cross-sectional study. J Pharm Bioallied Sci. 2015 Jul; 7(3):226.

Tuberculosis (TB) [Internet]. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention; 2018 [Updated 2018 Jan 1 cited 2018 Apr 9]. Available from: https://www.cdc.gov/tb/default.htm

Tuberculosis Types [Internet]. Tuberculosis Types - Tuberculosis – Health Communities.com. Stanley J. Swierzewski, III, M.D.; 2015 [Updated 08 Oct 2015 cited 2018Apr9]. Available from: http://www.healthcommunities.com/tuberculosis/types.shtml

Ravigilone MC. Tuberculosis. In: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J, editors. Harrison's Principles of Internal Medicine.19thed. New York: MC Graw Hill Education; 2015.p.1102- 1120.

Kays MB. Tuberculosis. In: Koda- Kimble MA, Young LY, Alldredge BK, Corelli RL, Guglielmo BJ, Kradjan WA, et al. Applied Therapeutics, the Clinical use of drugs.9thed.Philadelphia: Lippincott Williams and Wilkins; 2009.p. 61.1 - 61.20.

Namdar R, Lauzardo M, Peloquin CA. Tuberculosis. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, Editors. Pharamacotherapy, A Pathophysiologic Approach.9th ed. United States of America: MC Graw Hill Education; 2014.p. 1787- 1803.

Reid PT, Innes JA. Respiratory disease. In: Walker BR, College NR, Ralston SH, Penman ID, editors. Davidson's Principles and Practice of Medicine.22nd ed. Edinburgh: Churchill Livingstone Elsevier; 2014.p.688- 696.

Treatment of Tuberculosis: Guidelines. 4th edition. Geneva: World Health Organization;2010.Availablefrom: https://www.ncbi.nlm.nih.gov/books/NBK138748

Pandit N, Choudhary SK. A study of treatment compliance in directly observed therapy for tuberculosis. Indian J Community Med. 2006 Oct 1;31(4):241-3.

Gelmanova IY, Keshavjee S, Golubchikova VT, Berezina VI, Strelis AK, Yanova GV, Atwood S, Murray M. Barriers to successful tuberculosis treatment in Tomsk, Russian Federation: non-adherence, default and the acquisition of multidrug resistance. Bulletin of the World Health Organization. 2007 Sep; 85(9):703-11.

Al-Hajjaj MS, Al-Khatim IM. High rate of non-compliance with anti-tuberculosis treatment despite a retrieval system: a call for implementation of directly observed therapy in Saudi Arabia. Int J Tuberc Lung Dis. 2000 Apr 1; 4(4):345-9.

Muture BN, Keraka MN, Kimuu PK, Kabiru EW, Ombeka VO, Oguya F. Factors associated with default from treatment among tuberculosis patients in Nairobi province, Kenya: a case control study. BMC public health. 2011 Dec; 11(1):696.

Wares DF, Singh S, Acharya AK, Dangi R. Non-adherence to tuberculosis treatment in the eastern Tarai of Nepal. Int J Tuberc Lung Dis. 2003 Apr 1;7(4):327-35.

Slama K, Tachfouti N, Obtel M, Nejjari C. Factors associated with treatment default by tuberculosis patients in Fez, Morocco. East Mediterr Health J. 2013; 19 (8), 687 – 693.

Balabanova Y, Drobniewski F, Fedorin I, Zakharova S, Nikolayevskyy V, Atun R, Coker R. The directly observed therapy short-course (DOTS) strategy in Samara Oblast, Russian Federation. Respiratory Research. 2006 Dec; 7(1):44.

Amoran OE, Osiyale OO, Lawal KM. Pattern of default among tuberculosis patients on directly observed therapy in rural primary health care centres in Ogun State, Nigeria.J. Infect. Dis. Immun. 2011 May 31;3(5):90-5.

Bhagat VM, Gattani PL. Factors affecting tuberculosis retreatment defaults in Nanded, India Southeast Asian J Trop Med Public Health. 2010 Sep 1; 41(5):1153.

Chee CB, Boudville IC, Chan SP, Zee YK, Wang YT. Patient and disease characteristics, and outcome of treatment defaulters from the Singapore TB control unit—a one-year retrospective survey. Int J Tuberc Lung Dis. 2000 Jun 1;4(6):496-503.

Jaggarajamma K, Sudha G, Chandrasekaran V, Nirupa C, Thomas A, Santha T, Muniyandi M, Narayanan PR. Reasons for non-compliance among patients treated under Revised National Tuberculosis Control Programme (RNTCP), Tiruvallur district, south India. Ind J Tub. 2007; 54(3):130-5.

Tekle B, Mariam D, Ali A. Defaulting from DOTS and its determinants in three districts of Arsi Zone in Ethiopia.Int J Tuberc Lung Dis. 2002 Jul 1;6(7):573-9.

Daniel OJ, Oladapo OT, Alausa OK. Default from tuberculosis treatment programme in Sagamu, Nigeria. Niger J Med. 2006 Jan;15(1):63-7.

Kruyt ML, Kruyt ND, Boeree MJ, Harries AD, Salaniponi FM, Van Noord PA. True status of smear-positive pulmonary tuberculosis defaulters in Malawi. Bulletin of the World Health Organization. 1999; 77(5):386.

Kruk ME, Schwalbe NR, Aguiar CA. Timing of default from tuberculosis treatment: a systematic review. Trop. Med. Int. Health. 2008 May 1; 13(5):703-12.

Sanchez-Padilla E, Marquer C, Kalon S, Qayyum S, Hayrapetyan A, Varaine F, Bastard M, Bonnet M. Reasons for defaulting from drug-resistant tuberculosis treatment in Armenia: a quantitative and qualitative study. Int J Tuberc Lung Dis. 2014 Feb 1; 18(2):160-7.

Jaiswal A, Singh V, Ogden JA, Porter JD, Sharma PP, Sarin R, Arora VK, Jain RC. Adherence to tuberculosis treatment: lessons from the urban setting of Delhi, India. Trop. Med. Int. Health. 2003 Jul 1; 8(7):625-33.

Castelnuovo B. Review of compliance to anti-tuberculosis treatment and risk factors for defaulting treatment in Sub Saharan Africa. African health sciences. 2010; 10(4).

Oboyle S, Power J, Ibrahim MY, Watson J. Factors affecting patient compliance with anti-tuberculosis chemotherapy using the directly observed treatment, short-course strategy (DOTS). Int J Tuberc Lung Dis. 2002 Apr 1; 6(4):307-12.

Sagbakken M, Frich JC, Bjune G. Barriers and enablers in the management of tuberculosis treatment in Addis Ababa, Ethiopia: a qualitative study. BMC Public health. 2008 Dec;8(1):11.

A Prospective Observational Study on Adverse Drug Reactions in General Medicine Department of a Tertiary Care Teaching Hospital

Abstract Views :169 | PDF Views:0

Authors

N. M. Rayees ¹, Sampath Kumar ², K. C. Bharath Raj ¹, K. S. Rajesh ¹, Juno J. Joel ¹, K. Prasanna Shama ³, M. P. Gururaja ³, U. P. Nandakumar ¹

Affiliations
1 Department of Pharmacy Practice, NITTE (Deemed to be University), Mangaluru- 575018 Karnataka, IN
2 Department of General Medicine, NITTE (Deemed to be University), Mangaluru- 575018 Karnataka, IN
3 Department of Pharmacology, NITTE (Deemed to be University), Mangaluru- 575018 Karnataka, IN

Source

Research Journal of Pharmacy and Technology, Vol 12, No 5 (2019), Pagination: 2289-2298

Abstract

Present study was carried out to estimate the incidence of ADRs reported in general medicine department, to evaluate the causality, severity and preventability of ADRs caused by any drugs. A prospective observational study was carried out for a period of 8 months. Patients admitted during the study period were included as per the study criteria and monitored for ADRs. The clinical system, spectrum of ADRs noted and assessment of ADRs was done by causality, preventability and severity. The different scales are applied for assessment of causality, severity and preventability. Data was analysed by using descriptive statistics. A total number of 270 patients were included. 55 ADRs were observed in 52 patients. Higher incidence of suspected ADRs were exhibited with the age group of 61-70 years. The hospital stay extended for more than nine days in 32 (61.5%) patients who experienced ADR. The causality assessment by WHO Probability Scale, showed that out of 55 ADRs, majority were probable 38 (69.09%), whereas 11 (22%) reactions were possible and 6 (10.91%) reactions were certain. Based on Naranjo’s scale, 29 (52.73%) reactions were probable and 26 (47.27%) reactions were possible. Majority of 29 (53%) reactions were moderate in severity. Proper monitoring of adverse reactions is useful to minimize the incidence of ADRs and prevent further occurrence of the same. The regular monitoring of ADRs can reduce the morbidity and can improve the patients compliance which in turn can produce better therapeutic outcome.

Keywords

Adverse Drug Reaction, Causality, Severity, Preventability, Naranjo’s Scale.

Full Text

References

The Importance of Pharmacovigilance-Safety Monitoring of medicinal products. World Health Organisation. 2002.

WHO- International drug monitoring the role of national centres. Tech Rep Ser WHO 1972, no 498. https://www.whoumc.org/media/2680/who-technical-report498.pdf. Last accessed on 10 Dec 2016.

Asscher AW, Parr GD, Whitmarsh VB. Towards the safer use of medicines Br Med J. 1995; 311: 1003-1005.

Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. The lancet. 2000 Oct 7; 356(9237):12559.

Schatz S, Weber R. Adverse drug reactions. Pharmacy Practice. 2015 Aug 24; 1:1.

Flores R. Epidemiology of ADRs in Internal Medicine, HCC. Journal of Life Sciences. 2016; 10:54-7.

Roden DM. Principles of clinical pharmacology. In: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J, editors. Harrison’s Principles of Internal Medicine. 19 th edition. Newyork: MC Graw Hill Education; 2015.P.43-44.

Rawlins MD, Thomas SH. Mechanism of adverse drug reaction. In: Davies DM, Ferner RE, Glanville H, editors. Davies’s Text book of adverse drug reaction. 5th edition. UK: Chapman and Hall medical; 1998.P.40-41.

Tangiisuran B, Scutt G, Stevenson J et al. Development and validation of a risk model for predicting adverse drug reactions in older people during hospital. Stay: Brighton Adverse Drug Reactions Risk (BADRI) Model. PLOS One. 2014; 9:e111254.

Suke SG, Kosta P, Negi H. Role of pharmacovigilance in India: An overview. Online journal of public health informatics. 2015; 7(2).

World Health Organization Uppsala Monitoring Centre (WHO-UMC) causility assessment system.

Naranjo CA, Busto U Sellars EM, Sandor P, Ruiz i, Roberts EA, Janecek E. Method for estimating the probability of adverse drug reactions. ClinPharmacolTher. 1981; 30:239-245.

Hartwig SC, Seigel J and Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992; 49:2229-2232.

Shrivastava M, Uchit G, Chakravarti A, Joshi G, Mahatme M, Chaudhari H. Adverse drug reactions reported in Indira Gandhi government medical college and hospital, Nagpur. J Assoc Physicians India. 2011 May; 59:296-9.

Adhikari A Bhattacharjee N, Bhattacharya S, Indu R, Ray M. Evaluation of Frequency Adverse Drug Reactions in Tertiary Care Hospital of Kolkata. J Young Pharm. 2017; 9(3):311-314.

Asawari R, Atmaram P, Madhu P. Clinical Pattern and Severity of Cutaneous Adverse Drug Reactions. Int J Pharm Pharm Sci.2013; 5(2): 612-616.

Sriram S, Ghasemi A, Ramasamy R, Devi M, Balasubramanian R, Ravi TK et al. Prevalence of Adverse drug reactions at a private tertiary care hospital in south in india. J Res Med Sci. 2011; 16(1):16-25.

Lokesh Kumar. Pharmacovigilance/Reporting Adverse Drug Reactions: An approach to enhance health surveillance and extending market share by minimizing the chances of drug withdrawals. Int J Pharm Pharm Sci. 2015; 7(9): 1-7.

Prasad Rv, Pasha MAM, Fatima A, Deepalatha C. A demographic study on gender related differences in adverse drug reactions of a tertiary care teaching hospital. Int J Community Med Public Health. 2017 Jul; 4(7):2344-2347.

Khurshid F, Aqil M, Alam MS, Kapur P, Pillai KK. Monitoring of adverse drug reactions associated with antihypertensive medicines at a university teaching hospital in New Delhi. Daru. 2012 Sep 1; 20(9):1.

Singh H, Dulhani N, Kumar BN, Singh P, Tewari P, Nayak K. A Pharmacovigillance Study in Medicine of Tertiary Care Hospital in a Chhattisgarh (Jagdalpur), India. J Young Pharm. 2010; 2(1):95-100.

Vora MB, Trivedi HR, Shah BK, Tripathi CB. Adverse drug reactions in inpatients of internal medicine wards at a tertiary care hospital: A prospective cohort study. Journal of pharmacology and pharmacotherapeutics. 2011 Jan; 2(1):21.

Davies EC, Green CF, Taylor S, Williamson PR et al. Adverse Drug Reactions in Hospital In-patients: A prospective Analysis of 3695 Patient- Episodes. PloS one February 2009; 4(2) 4439:1-7.

Shareef J, Vincen M, Shastry CS. A Prospective Study On Adverse Drug Reactions In A Tertiary Care Teaching Hospital. Am. J. PharmTech Res. 2013; 3(6):508-517.

Prajapati K, Desai M, Shah S, Panchal J, Kapadia J, Dikshit R. An analysis of serious adverse drug reactions at a tertiary care teaching hospital. PerspectClin Res 2016; 7:181-186.

Ramakrishnaiah H, Krishnaiah V, Pundarikaksha HP, Ramakrishna VB. A prospective study on adverse drug reactions in outpatients and inpatients of medicine department in a tertiary care hospital. Int J Basic ClinPharmacol. 2015 Jun; 4(3):515-521.

Username
Password
Remember me